Advance Online
Image of coronavirus molecule.

NPF Forms COVID-19 Task Force

This group of medical and scientific experts have collaborated to provide updated recommendations for people with psoriatic disease and will guide NPF in response to the ongoing pandemic and beyond.

As the SARS-CoV-2 coronavirus spread early in the year, the National Psoriasis Foundation (NPF) recognized the critical need for additional information for health care providers and individuals living with psoriatic disease on managing psoriasis and psoriatic arthritis during the COVID-19 pandemic. In March 2020 NPF released “NPF Medical Board COVID-19 Recommendations for Patients with Psoriatic Disease,” which provided early guidance for the community based on information available at that time.

In May, to effectively serve the psoriatic disease community through this pandemic and to closely monitor evolving data and advances, NPF formed the NPF COVID-19 Task Force. This group, which is chaired by dermatologist Joel M. Gelfand, MD, MSCE, FAAD and rheumatologist Christopher T. Ritchlin, M.D., M.P.H., is comprised of experts from both the NPF Medical Board and Scientific Advisory Committee and consists of experts in dermatology, rheumatology, infectious disease and critical care. The charge of the Task Force is to identify critical needs for the psoriasis and psoriatic arthritis community related to the pandemic and to serve as an expert resource to NPF in an advisory capacity. The group will address short-, mid- and long-term needs. 

One of the first activities of the task force was to review and update the preliminary recommendations of NPF medical and scientific leaders. In early June, the NPF COVID-19 Task Force released updated recommendations for the community.

The most recent update, which took place August 20, is the result of a modified Delphi process that was conducted asking the Task Force members to provide consensus on important questions posed by patients and providers. As part of this process, the Task Force co-chairs completed weekly literature searches for COVID-19 in relation to psoriatic disease. Using this evidence-based information, guidance statements were developed and underwent 2 rounds of voting with discussion in between. The Task Force members reached consensus on 22 guidance statements for the psoriatic disease community, with 9 statements receiving high consensus and the remaining 13 statements receiving moderate consensus.

Health care providers and patients are encouraged to visit NPF’s COVID-19 Resource Center for the latest guidance from the Task Force, in order to promote optimal care and outcomes for patients with psoriatic disease during the pandemic.

COVID-19 Task Force Guidance Statements

Updated August 20, 2020

More Resources and Information

Our COVID-19 Resource Center has news, updates, stories and recommendations from the experts on COVID-19 and psoriatic disease.

Stay in the Know.

Expert tips, can’t-miss events and the latest news, straight to your inbox.

National Health Council Standards of ExcellenceCharity Navigator

Copyright © 1996-2020 National Psoriasis Foundation/USA


Duplication, rebroadcast, republication or other use of content appearing on this website is prohibited without written permission of the National Psoriasis Foundation (NPF).


NPF does not endorse or accept any responsibility for the content of external websites.


NPF does not endorse any specific treatments or medications for psoriasis and psoriatic arthritis.

We use cookies to offer you a better experience and analyze our site traffic. By continuing to use this website, you consent to the use of cookies in accordance with our Privacy Policy.